Radioactive seeds plus immunotherapy: a new hope for Hard-to-Treat head and neck cancer?
NCT ID NCT05047094
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a new approach for people with head and neck cancer that has come back or spread and cannot be removed. It combines a device called DaRT, which is a tiny radioactive seed placed directly into the tumor, with the immunotherapy drug pembrolizumab (Keytruda). The goal is to see if this combination can shrink tumors and control the disease. About 48 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Diffusing Alpha Radiation Emitters Therapy (DaRT) device and pembrolizumab (Keytruda)
What this could lead to
If it works, this could offer a new treatment option for people with head and neck cancer that has come back or spread and cannot be removed by surgery.
What could go wrong
This is an early-stage trial with only 48 participants, so results may not apply to everyone. The combination of radiation and immunotherapy may cause side effects like inflammation or immune reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sharett institute, Hadassah University Hospital - Ein-Kerem
RECRUITINGJerusalem, 91120, Israel
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tel-Aviv Medical Center
NOT_YET_RECRUITINGTel Aviv, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••